Kiniksa to Present Preclinical Data on the GM-CSF Signaling Pathway in Temporal Arteries of GCA Patients at EULAR 2019

World News: . []

HAMILTON, Bermuda, May 30, 2019 (GLOBE NEWSWIRE) -- (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present preclinical data on the increased expression of granulocyte macrophage colony stimulating factor (GM-CSF) signaling pathway in temporal arteries of giant cell arteritis (GCA) patients at the European League Against Rheumatism’s (EULAR) 2019 Annual Meeting being held in Madrid, Spain, June 12 - 15, 2019.

Poster Presentation Details:

The abstract is available through the Investors and Media section of Kiniksa’s website (). Kiniksa intends to make the poster available through the Investors and Media section of its website after the EULAR embargo lifts, which is expected to be at approximately 12:00 a.m. CET on June 12, 2019.

More news and information about Kiniksa Pharmaceuticals, Ltd.

Published By:

Globe Newswire: 21:01 GMT Thursday 30th May 2019

Published: .

Search for other references to "kiniksa" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us